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Abstract
Introduction Belimumab, an anti-B-lymphocytestimulator antibody, is approved for the treatment of active,
autoantibody-positive systemic lupus erythematosus (SLE).
Rituximab, a B cell-depleting anti-CD20 antibody, remains
in the SLE treatment armamentarium despite failed trials
in lupus nephritis and extrarenal lupus. These biologics,
which operate through complementary mechanisms, might
result in an enhanced depletion of circulating and tissueresident autoreactive B lymphocytes when administered
together. Thus, belimumab and rituximab combination may
be a highly effective treatment of SLE. This study aims to
evaluate and compare the efficacy, safety and tolerability
of subcutaneous (SC) belimumab and a single cycle of
rituximab in patients with SLE with belimumab alone.
Methods and analysis BLISS-BELIEVE is a three-arm,
randomised, double-blind, placebo-controlled, 104-week
superiority study. Two hundred adults with SLE will be
randomised 1:2:1 to arm A, belimumab SC 200 mg/
week for 52 weeks plus placebo at weeks 4 and 6;
arm B, belimumab SC 200 mg/week for 52 weeks plus
rituximab 1000 mg at weeks 4 and 6; arm C, belimumab
SC 200 mg/week plus standard of care for 104 weeks.
The 52-week treatment period (arms A and B) is followed
by a 52-week observational phase. The primary efficacy
endpoint is the proportion of patients with disease control
(SLE Disease Activity Index (SLEDAI)−2K≤2, without
immunosuppressants and with a prednisone-equivalent
dose of ≤5 mg/day) at week 52. Major secondary
efficacy endpoints are the proportion of patients in
clinical remission (defined as SLEDAI-2K=0, without
immunosuppressants and corticosteroids) at week 64, and
the proportion of patients with disease control at week
104. Safety endpoints include the incidence of adverse
events (AEs), serious AEs and AEs of special interest.
Ethics and dissemination Within 6 months of the study’s
primary manuscript publication, anonymised individual
participant data and study documents can be requested

Strengths and limitations of this study
►► This study builds on the experience of randomised

controlled trials of the biologics belimumab and
rituximab used as single agents, as well as preclinical findings, case studies and open-label trials of
belimumab and rituximab combination treatment.
►► The unique sequence of treatment administration
and assessment of the clinically relevant outcomes
of disease control and disease remission are novel
features of this study.
►► BLISS-BELIEVE is the first randomised trial to carry out observations for 52 weeks after stopping
belimumab treatment, allowing for the assessment
of true disease remission and its durability.
►► BLISS-BELIEVE randomises patients to a third treatment arm of belimumab plus standard-of-care therapy to reflect current real-life practice.
►► The study is limited by a relatively small sample
size, and thus has limited power to detect infrequent
adverse events.
for further research from www.clinicalstudydatarequest.
com.
Trial registration number NCT03312907; Pre-results.

Introduction
Immune-mediated inflammatory diseases
(IMIDs) share some common molecular pathways that lead to inflammation, which results
from dysregulation of the normal immune
response. Chronic inflammation in IMIDs is
associated with progressive tissue damage as
well as increased comorbidity and mortality.
Systemic lupus erythematosus (SLE) and
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Sjögren’s syndrome are both prototypic antibody-dependent IMIDs.1 SLE is a chronic multisystem inflammatory
autoimmune disease associated with impaired health-related quality of life.2 3 The ultimate goals of SLE treatment are disease remission, damage prevention (from
both disease progression and prolonged use of medication) and normalisation of health-related quality of life.4 5
These goals are difficult to achieve in most patients owing
to limitations in the efficacy of, and long-term toxicity
associated with, conventional treatments for SLE, such as
corticosteroids and immunosuppressants.6 7
Patients with SLE have elevated levels of circulating B-lymphocyte stimulator (BLyS), a member of
the tumour necrosis factor ligand superfamily that
promotes B cell activation and differentiation.8–10
Increased serum BLyS levels in patients with SLE are
associated with disease activity, disease relapse and
increased numbers of autoantibody-secreting plasma
cells, linking BLyS to the pathogenesis of SLE.9 11
Belimumab, a recombinant immunoglobulin G1λ
human monoclonal antibody, binds to and antagonises
the biological activity of soluble BLyS.12 It has shown
efficacy in patients with autoantibody-positive active
SLE in multiple trials.13–16 Belimumab-treated patients
also experienced fewer disease flares, and showed a
reduction in steroid use and long-term organ damage
accrual compared with patients receiving standard of
care (SoC).13–17 While the efficacy of belimumab has
been demonstrated in patients with SLE, a proportion
of patients maintain a degree of disease activity despite
belimumab treatment.13–16 Therefore, additional effective and well-tolerated treatment options are required
to further improve overall disease control.
Rituximab is a B cell-depleting, anti-CD20 monoclonal
antibody that showed promise in several open-label clinical studies,18–22 but failed to demonstrate efficacy in two
randomised trials in SLE and lupus nephritis.23 24 In autoimmune diseases, rituximab treatment results in rapid
and near-complete depletion of circulating CD20+ B
cells; however, relatively high numbers of B cells persist
in tissues, such as bone marrow, kidneys, synovium and
salivary glands.25–29 In SLE, an increase in BLyS levels
after rituximab treatment may contribute to survival and
rebound of autoreactive B cells and subsequent disease
flares,30 31 as demonstrated in several cohort studies.32–34
Consistent with these observations, reduced maturation
of autoreactive B cells during B cell reconstitution was
observed in mice treated with an agent that blocked B cell
activating factor.35
Combining belimumab with rituximab therefore has
a strong immunological rationale, as the drugs operate
through complementary and perhaps synergistic mechanisms.36 Belimumab treatment results in the mobilisation of memory B cells from tissues despite an overall
decrease in peripheral B cell levels.37 This phenomenon will render tissue-resident B cells more susceptible
to depletion by rituximab. In addition, blocking the
effects of high serum BLyS levels might have favourable
2

quantitative and qualitative effects on B cell reconstitution after depletion.31 Synergistic or additive effects of
such a combination have indeed been demonstrated in
preclinical studies in lupus-prone mice. Improved tissue
B cell subset depletion, a decrease in the levels of autoantibodies, reduced proteinuria and improved survival were
observed with combination therapy compared with either
treatment alone.38–40
This hypothesis is further supported by case
reports in patients with SLE, lupus nephritis and
Sjögren’s syndrome,41–45 and prompted the SynBioSe
study, which showed significant clinical and immunological improvements from baseline in patients with refractory
SLE who received rituximab and belimumab.46 Several
clinical trials are currently investigating belimumab and
rituximab combination therapy in primary Sjögren’s
syndrome (NCT02631538), lupus nephritis (CALIBRATE;
NCT02260934) and SLE (BEAT Lupus; ISRCTN47873003).
We hypothesised that durable low disease activity might
be achieved in patients with active SLE by resetting the
autoreactive humoral immune system. Therefore, we have
designed the BLISS-BELIEVE study to examine whether
combination treatment with belimumab and rituximab
could induce a pre-defined state of disease control or
disease remission, allowing the tapering of conventional
SLE therapies. This study will employ a novel sequence
of belimumab and rituximab combination therapy and
investigate novel study endpoints, which could potentially
shift the current paradigm of SLE treatment.
The objective of this study is to evaluate the efficacy,
safety and tolerability of subcutaneous (SC) belimumab
and a single cycle of rituximab administered in a combination regimen in adult patients with SLE compared with
belimumab alone.

Methods and analysis
Study design
This is a phase III, multicentre, three-arm, randomised,
double-blind, placebo-controlled, 104-week superiority study (BEL205646; NCT03312907). There will be
a 52-week double-blind treatment period followed by
a 52-week double-blind observational treatment-free
follow-up period in arms A and B (to week 104) (figure 1).
The study began recruitment in March 2018, with an estimated final completion in June 2021.
Study population
Detailed inclusion and exclusion criteria are listed in
box 1. Briefly, patients must be ≥18 years of age, with a clinical diagnosis of SLE according to the American College
of Rheumatology criteria, and an SLE Disease Activity
Index (SLEDAI)-2K score ≥6 at screening. Patients with
severe lupus nephritis or severe active central nervous
system lupus will be excluded. Informed consent will be
obtained from patients prior to the initiation of any study
procedures or study-specific data collection.
Teng YKO, et al. BMJ Open 2019;9:e025687. doi:10.1136/bmjopen-2018-025687
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Figure 1

Study design. IV, intravenous; PBO, placebo; RTX, rituximab; SC, subcutaneous; SoC, standard of care; W, week.

Randomisation
Patients will be randomised 1:2:1 to one of three treatment arms: belimumab plus placebo (arm A, control),
belimumab plus rituximab (arm B, combination) or
belimumab plus SoC (arm C, reference). At randomisation, patients will be stratified by their screening
SLEDAI-2K score (≤9 vs ≥10), immunosuppressant use
(immunosuppressant use vs no use) and corticosteroid
dose (prednisone equivalent ≤10 mg/day vs >10 mg/day).
Randomisation, and the first dose of belimumab, should
be completed within 35 days of the initiation of screening.
Blinding
The study is double-blind with regards to whether participants are randomised to arm A or arm B. Randomisation
to arm C will not be blinded. To minimise bias given that
arm C is open-label, independent assessors blinded to
treatment group will conduct the SLEDAI-2K assessments
at selected visits for the primary and major secondary efficacy endpoints. Unblinded safety data will be reviewed
regularly by an independent data monitoring committee.
Study treatments
Patients randomised to arm A (control) will receive
belimumab SC 200 mg/week for 52 weeks with a cycle
of intravenous placebo (rituximab-matched; dose 1
at week 4 and dose 2 at week 6). Patients randomised
to arm B (combination) will receive belimumab SC
200 mg/week for 52 weeks with a cycle of rituximab
intravenously (1000 mg doses given at week 4 and
week 6). Patients randomised to arm C (reference)
will receive belimumab SC 200 mg/week plus SoC,
including immunosuppressants, for 104 weeks. Patients
in arms A and B will be administered a premedication
regimen 30 min before each placebo or rituximab
infusion, consisting of methylprednisolone intravenously 100 mg or equivalent, an oral antihistamine and
acetaminophen or equivalent (table 1).
After completing week 52, patients in arms A and B
will enter into the 52-week treatment-free (defined as
no active treatment with belimumab and/or rituximab),
Teng YKO, et al. BMJ Open 2019;9:e025687. doi:10.1136/bmjopen-2018-025687

observational phase of the study (weeks 53 through 104).
Patients in arm C will continue to receive belimumab
SC and stable immunosuppressants during this phase.
In addition, treatment with antimalarials, non-steroidal
anti-inflammatory drugs and corticosteroids (prednisone
equivalent ≤5 mg/day) is allowed in the observational
phase in all three arms.
Patients considered treatment failures (patients in arm
A or B who fail to respond adequately to study treatment,
who do not meet the corticosteroid taper rules or tolerate
immunosuppressant withdrawal at week 4, or who require
additional therapy) will be encouraged to remain in the
study to receive all safety and efficacy assessments through
week 104. During this time (weeks 53–104), additional
treatment may be given, if deemed of benefit by the investigator, to patients with responses that do not reach the
predefined study criteria for disease control (as defined
in the study endpoints), or subsequently experience
increased disease activity. This treatment can include
belimumab, corticosteroids, and/or immunosuppressants; additional treatment with rituximab will be
permitted, but not encouraged.
Concomitant medications
Patients randomised to arms A and B who enter the study
on immunosuppressants will discontinue immunosuppressants at or prior to the week 4 visit. Patients in arm
C who enter the study on stable immunosuppressants
may continue to receive them throughout the study.
After the initial 12 weeks of study treatment, a protocol-specified corticosteroid taper will be initiated for all
three arms (carried out under the direction of the investigator), with a target of reaching a prednisone equivalent dose of ≤5 mg/day by week 26. After week 26, if a
patient’s average daily corticosteroid dose exceeds 5 mg/
day prednisone equivalent, the patient will be declared a
treatment failure. Antimalarials and non-steroidal anti-inflammatory drugs may be used throughout the study for
all treatment arms.
3
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Box 1

Patient inclusion and exclusion criteria

Inclusion criteria
►► ≥18 years of age
►► Clinical diagnosis of SLE according to the ACR criteria
►► Minimum screening SLEDAI-2K score ≥6
►► Unequivocally positive ANA and/or anti-dsDNA test results from two

independent time points
►► Stable SLE treatment regimen
►► Female patients who are not pregnant, not breastfeeding, not of

childbearing potential or follow contraceptive guidance
Exclusion criteria
►► Symptomatic herpes zoster within 3 months prior to screening
►► Active or latent TB, confirmed by medical history and examination,
chest X-rays and TB testing: either a positive TST (defined as a skin
induration ≥5 mm at 48–72 hours, regardless of BCG or other vaccination history), or a positive QuantiFERON-TB Gold test
►► Allergies to humanised monoclonal antibodies
►► Clinically significant multiple or severe drug allergies and/or history
of hypersensitivity to belimumab and/or rituximab
►► Lymphoma, leukaemia, or any malignancy within the past 5 years
►► ALT >2 x ULN
►► Bilirubin >1.5 x ULN
►► IgA <10 mg/dL
►► IgG <250 mg/dL
9
►► Neutrophils <1.5×10
►► Unstable liver or biliary disease
►► Severe heart failure
►► QTc>450 msec or>480 ms in patients with bundle branch block
►► History of a major organ transplant
►► Clinical evidence of significant unstable or uncontrolled acute or
chronic diseases not due to SLE
►► Acute or chronic infection requiring management
►► Severe lupus kidney disease
►► Severe active central nervous system lupus
►► Planned surgical procedure, laboratory abnormality or condition that
makes the patient unsuitable for the study
►► Evidence of serious suicide risk
►► History of an anaphylaxis reaction to parenteral administration of
contrast agents, human/murine protein, or monoclonal antibodies
►► Live vaccine(s) within 1 month prior to screening
►► Within 364 days of day 1, received certain biologics (belimumab,
rituximab, abatacept, a B cell-targeted therapy, a biological investigational agent other than B cell-targeted therapy), or required three
or more courses of systemic corticosteroids
►► Within 90 days of day 1, received anti-TNF therapy, interleukin-1
receptor antagonist, intravenous immunoglobulin, high-dose prednisone or equivalent, or plasmapheresis
►► Within 60 days of day 1, received a non-biological investigational
agent, intravenous cyclophosphamide, a steroid injection
►► Positive HIV antibody test
►► Positive serology for hepatitis B or hepatitis C
►► Current or history (within 364 days of day 1) of drug/alcohol
dependence
►► Sensitivity to any of the study treatments or components
►► Unable to administer belimumab by SC injection
ACR, American College of Rheumatology; ALT, alanine aminotransferase;
ANA, anti-nuclear antibodies; BCG, Bacillus Calmette-Guerin; HIV, human
immunodeficiency virus; IgA, immunoglobulin A; IgG, immunoglobulin G; QTc,
corrected QT; SC, subcutaneous; SLE, systemic lupus erythematosus; SLEDAI2K, SLE Disease Activity Index; TB, tuberculosis; TNF, tumour necrosis factor;
TST, tuberculin skin test; ULN, upper limit of normal.
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Other investigational agents (or co-enrolment into
another study of a different investigational agent), antitumour necrosis factor therapy, other biologics with effects
on the immune system, immunoglobulin intravenously,
cyclophosphamide intravenously and plasmapheresis
are prohibited throughout the study.
Study endpoints
The primary efficacy endpoint is the proportion of
patients with disease control at week 52, defined as a
SLEDAI-2K score of ≤2, achieved without immunosuppressants and with a prednisone equivalent dose
of ≤5 mg/day. The major secondary efficacy endpoints are
the proportion of patients in clinical remission at week
64 (defined as a clinical SLEDAI-2K score of 0, allowing
for serologies of anti-dsDNA and hypocomplementaemia
and achieved without immunosuppressants and corticosteroids), and the proportion of patients with disease
control at week 104 (defined as a SLEDAI-2K score of ≤2,
achieved without immunosuppressants and with a prednisone-equivalent dose of ≤5 mg/day). Patient-reported
outcome measures include change from baseline in
Patient Global Assessment (PtGA), LupusQoL domain
summary scores and Functional Assessment of Chronic
Illness Therapy (FACIT)-Fatigue score, and proportion
of patients with an improvement in FACIT-Fatigue score
exceeding the minimal clinically-important difference.
Safety endpoints include the incidence of adverse events
(AEs), including serious AEs (SAEs) and AEs of special
interest (AESI). The endpoints will be assessed using the
measures listed in box 2.
Sample size calculation
Approximately 400 patients will be screened, with a
goal of randomising at least 200 patients (50% screen
failure rate). A target of 50 patients will be randomised
in arms A and C, and 100 patients in arm B. This sample
size provides at least 95% power (for the comparison of
arm B to arm A at week 52) at a 5% level of significance,
assuming the underlying response in the control arm is
10%, and the true population effect is ≥25% with treatment arm B (assumed response rate of 35%). For the
primary endpoint, patients who drop out from the study
will be included in the analysis as non-responders; thus,
the assumed responder rates for arms A and B already
account for the rate of patient dropout. However, to
ensure adequate safety exposure in arm B, the sample size
may be increased up to 300 patients if the dropout rate
reaches 10% at the scheduled time point for receiving
both doses of placebo or rituximab.
Based on limited clinical data with therapies including
both belimumab and rituximab, opinions from external
experts, and the rarity of remission or disease control
seen in published studies, a rate of 35% of patients in
arm B achieving a state of disease control is considered
to be highly clinically significant in SLE care. A response
rate of 10% at week 52 was assumed for arm A (control),
based on historical data from three belimumab phase
Teng YKO, et al. BMJ Open 2019;9:e025687. doi:10.1136/bmjopen-2018-025687
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Table 1 Study treatment arms
Treatment

Arm A (control)

Arm B (combination)

Arm C (reference)

Belimumab

Belimumab SC
200 mg/week for
52 weeks
One cycle of placebo intravenously
(rituximab-matched) at week 4 and
week 6

Belimumab SC
200 mg/week for
52 weeks
One cycle of rituximab intravenously
1000 mg at week 4 and week 6

Belimumab SC
200 mg/week plus SoC
for 104 weeks
None

Methylprednisolone intravenously
100 mg or equivalent, oral
antihistamine, acetaminophen or
equivalent
Antimalarials,
NSAIDs and/or corticosteroids with a
prednisone equivalent dose of ≤5 mg/
day

Methylprednisolone intravenously
100 mg or equivalent, oral
antihistamine, acetaminophen or
equivalent
Antimalarials,
NSAIDs and/or corticosteroids
with a prednisone equivalent dose
of ≤5 mg/day

None

Rituximab or matched
placebo
Premedication (30 min
before each placebo or
rituximab infusion)
Post week 52 therapy

Continue belimumab
SC
200 mg/week plus
SoC*

*Patients in arm C are allowed to receive rescue therapy if, in the opinion of the investigator, they require additional treatment. This can
include corticosteroids at >5 mg/day prednisone equivalent.
NSAIDs, non-steroidal anti-inflammatory drugs; SC, subcutaneous; SoC, standard of care.

III trials. Assuming a 10% control responder rate and
50 patients in arm A and 100 patients in arm B, the
minimum detectable effect at p<0.05 is a 12% improvement (ie, an observed improvement of 12% or more in
arm B would give a p<0.05). A sample size sensitivity analysis was conducted on the primary endpoint to investigate
the impact on power if the assumed underlying control
response rate deviates from 10% or the treatment difference deviates from 25%.

Box 2 Study assessments
Efficacy assessment
SLEDAI-2K, a clinical index for measuring SLE disease activity in the
previous 10 days, at screening/baseline and at weeks 52, 64 and 104.
Safety assessment
Full physical examination, ECG, clinical safety laboratory assessments, neurological assessment, and suicidal risk monitoring
(assessed via C-SSRS) at screening. Symptom-driven physical examination, vital signs, clinical safety laboratory assessments, neurological
assessment, and suicidal risk monitoring at scheduled and unscheduled
visits.
Laboratory tests
Anti-dsDNA/ANA, complement C3/C4, serum immunoglobulin (IgG, IgA,
IgM), urine testing (urinalysis, spot urine protein), haematology and
blood chemistry, pregnancy test: performed at screening and at each
assessment visit. Autoantibody levels, including aCL, beta-2-glycoprotein, lupus anticoagulant, and extractable nuclear antigens, will be measured at day 1 and weeks 8, 26, 52, 60, 80 and 104.
B cell analyses
Pharmacokinetics
aCL, anticardiolipin; ANA, antinuclear antibodies; C, complement; C-SSRS,
Columbia-Suicide Severity Rating Scale; ECG, electrocardiogram; Ig,
immunoglobulin; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease
Activity Index.
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Statistical analyses
Unless otherwise stated, all analyses will be performed
on the intent-to-treat population. The key analyses will
compare belimumab with or without a single cycle of
rituximab (arm A vs arm B). Descriptive statistics will be
used to compare the combination of belimumab with
a single cycle of rituximab (arm B) versus belimumab
with SoC (arm C). The primary and major secondary
endpoints will be compared using a logistic regression
model. The independent variables will include treatment
group, baseline SLEDAI-2K score (≤9 vs ≥10), immunosuppressant use at baseline (immunosuppressant use vs
no use), and baseline corticosteroid dose (prednisone
equivalent ≤10 mg/day vs >10 mg/day). If any factor fails
to converge it will be removed from the logistic model. If
the model fails to converge (eg, owing to a small number
of responders), the endpoints will be analysed using a
Fisher’s exact test. Missing data are accounted for in the
primary efficacy endpoint, as all patients will be classified
as either a non-responder (including premature study
discontinuation or treatment failure prior to week 52)
or responder. Sensitivity analyses will be used to explore
the impact of missing data and treatment failure imputation. Descriptive statistics will be used to summarise
AEs, SAEs, AESI, changes in laboratory parameters, and
immunogenicity.
Ethical considerations
This study will be conducted in accordance with consensus
ethical principles derived from international guidelines,
including the Declaration of Helsinki and Council for
International Organisations of Medical Sciences International Ethical Guidelines, applicable International
Conference on Harmonisation Good Clinical Practice
Guidelines and applicable laws and regulations. SAEs will
5
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be reported by the investigator to the sponsor immediately, and no later than within 24 hours. Written informed
consent will be obtained from all patients, who will be
assigned a unique identifier; all patient records and data
transferred to the sponsor will contain the identifier only.
Dissemination
Study information will be publicly available at www.
clinicaltrials.
gov, and the results of this trial (positive
and negative) will be submitted for publication in relevant peer-reviewed publications and the key findings
presented at national and international conferences.
Within 6 months of the publication of the primary manuscript for this study, anonymised individual participant
data, the annotated case report form, protocol, reporting
and analysis plan, data set specifications, raw data set,
analysis-ready data set and clinical study report will be
available for research proposals approved by an independent review committee. Proposals should be submitted to
www.clinicalstudydatarequest.com. A data access agreement will be required. This paper complies with the
Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) recommendations for protocol
reporting.47
Patient and public involvement
Patients and/or public were not involved in the development of this study.

Discussion
This study aims to explore the potential for synergy
and to demonstrate greater efficacy of combination
treatment with belimumab and rituximab compared
with belimumab monotherapy in achieving low disease
activity, disease remission, or clinical quiescence in
patients with SLE. Although to date, combination
biologics have not been widely used in other diseases, we
think there is a strong immunological rationale to study
belimumab and rituximab combination therapy in the
context of SLE. The residual disease activity that many
patients with SLE experience despite current therapies
further justifies the exploration of this novel combination treatment. If this study confirms our hypothesis
that combined belimumab and rituximab treatment has
additional efficacy over standard belimumab care, then
this may transform the current treatment paradigm,
allowing patients with SLE to discontinue conventional,
often toxic medications.
The unique sequence of administering belimumab
and rituximab (which we believe will enhance B cell
depletion), the use of belimumab SC and a larger sample
size, differentiate the BLISS-BELIEVE study from BEAT
Lupus (ISRCTN47873003),48 a similar belimumab and
rituximab combination therapy, phase II trial in SLE that
is currently recruiting patients in the UK. The sequence
of treatment administration also differs from that used in
the CALIBRATE trial in lupus nephritis (NCT02260934).49
6

In addition, BLISS-BELIEVE is one of the first trials of
belimumab to carry out assessments for 52 weeks after stopping treatment, and investigate ambitious, clinically relevant outcomes of low disease activity or disease remission.
The 52-week observational, treatment-free phase provides
an opportunity to observe if a true disease remission occurs,
and allows for the assessment of the durability of any such
remission or low disease activity. In the treatment of SLE, it
is important to balance clinical efficacy and therapy-related
toxicity. The unique design of BLISS-BELIEVE will ensure
this is assessed through the use of rigorous endpoints (such
as clinical remission), and by enabling the termination of
belimumab if toxicity is an issue.
The unique treatment schedules were selected
according to a rationale based on the current evidence. In
the 52-week treatment phase, belimumab SC 200 mg will
be administered weekly as per the treatment regimen in
the phase III study of belimumab SC, which demonstrated
its safety and efficacy in patients with SLE.15 Rituximab
is not approved for the treatment of patients with SLE,
and no standard dosing regimen has been established.
Based on previous trials of rituximab that showed a lack
of efficacy, we deemed that a rituximab-only arm would
fail to meet standards of equipoise. In the current study,
rituximab dosing will follow one cycle of the approved
dosing recommendation for rheumatoid arthritis, which
is two doses of 1000 mg intravenously given 2 weeks apart.
In a phase II/III trial, this rituximab regimen demonstrated rapid depletion of CD19-positive cells (<5 cells/
µL) in the majority of patients with SLE.23 It is also the
dosing regimen recommended in NHS England’s Interim
Clinical Commissioning Policy Statement for rituximab
use in patients with refractory SLE.50 Furthermore,
belimumab and rituximab combination treatment has
previously shown acceptable safety and significant clinical
responses in patients with severe, refractory SLE.46
Separating the administration of belimumab and
rituximab may allow for observation of safety events
attributable to each treatment; however, owing to the
relatively small sample size, the study will have limited
power to detect less common AEs. With the consecutive
administration regimen, the study allows investigation
of the hypothesis that belimumab mobilises additional
CD20+ B cells into the circulation, making them available
for anti-CD20 treatment with rituximab. Therefore, we
will be able to further establish whether more efficient
depletion of autoreactive B cells, otherwise protected
from cell death in the tissue niches, is achieved.37 We
anticipate that there will be fewer autoreactive B cells
appearing in the memory B cell compartment during
the early phase of B cell reconstitution. However, we are
aware that the controls for this analysis are historical,
owing to the ethical considerations discussed above.
B cell mobilisation will be evaluated by comparing baseline, pre-belimumab B cell levels with autoreactive B
cells appearing in peripheral blood after belimumab
treatment. The possible reappearance of autoreactive B cells following rituximab treatment will then be
Teng YKO, et al. BMJ Open 2019;9:e025687. doi:10.1136/bmjopen-2018-025687

Open access
established by comparing B cells levels between the
belimumab-only and belimumab and rituximab arms.
This study has some limitations. Because rituximab
is not approved for the treatment of patients with
SLE, a rituximab-only arm could not be included in
the protocol. Therefore, some clinical and serological
outcomes attributable to rituximab treatment will not
be assessed. However, this study aims to explore whether
belimumab treatment can be optimised by sequential
treatment with rituximab, for which a rituximab-only
arm is not required. Another limitation of the study
design is that direct measurements of B cell depletion in tissue niches will not be performed. However,
this measurement and a rituximab-only arm are being
explored in a clinical trial of belimumab and rituximab
combination therapy in primary Sjögren’s syndrome
(NCT02631538), which follows a similar administration
regimen. Another concern is that patients in study arms
A and B will discontinue immunosuppressants from
week 4, which might result in a higher than predicted
treatment failure rate, due to flares occurring before
belimumab and rituximab achieve therapeutic efficacy
at week 12. However, the risk of disease flares to patients
will be mitigated by methylprednisolone pretreatment
and the option for investigators to adjust concomitant
corticosteroid treatment as clinically necessary up to
week 26. Although substantially different from previous
belimumab trials, such as BLISS-76, in which more than
half the patients continued on background immunosuppressive agents,12 this regimen will allow investigation of whether belimumab and rituximab combination
therapy could result in an immunologically more favourable condition in some patients, thus enabling the
tapering of conventional immunosuppressive drugs
and possibly an immunosuppressant-free honeymoon.
A positive outcome of BLISS-BELIEVE would further
support the rationale to test this therapeutic strategy in
Sjögren’s syndrome and other autoantibody-dependent
IMIDs.
In conclusion, the BLISS-BELIEVE study is supported
by strong scientific rationale from preclinical studies, case
reports and open-label trials. Its pioneering and unique
design will allow for a long-term observation of true
clinical remission, assessment of the durability of such
a remission state and assessment of any potential safety
issues. The results of this study may support the rationale
for combination therapy in other autoimmune conditions. BLISS-BELIEVE began recruitment in March 2018,
with estimated study completion in June 2021.
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